Safety and Immunogenicity of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine (GSK1562902A) in Children Aged 6 to 35 Months.
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Oct 2011 Planned end date changed from 1 Aug 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.